<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methimazole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methimazole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methimazole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11222" href="/d/html/11222.html" rel="external">see "Methimazole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12592" href="/d/html/12592.html" rel="external">see "Methimazole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24520218"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tapazole [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867504"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Methimazole;</li>
<li>Mar-Methimazole;</li>
<li>Tapazole</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F194348"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antithyroid Agent;</li>
<li>
                        Thioamide</li></ul></div>
<div class="block doa drugH1Div" id="F194318"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d10a9db5-9833-4984-8b04-ce74e23a21b3">Hyperthyroidism associated with Graves disease, toxic multinodular goiter, toxic adenoma, or iodine-induced thyrotoxicosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism associated with Graves disease, toxic multinodular goiter, toxic adenoma (labeled uses), or iodine-induced thyrotoxicosis (off-label use)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May use in combination with beta-blockade to manage hyperthyroid symptoms prior to definitive therapy (ie, radioactive iodine therapy or surgery) or as chronic low-dose treatment; for iodine-induced thyrotoxicosis, may be used as an adjunct to beta-blockade for severe or prolonged (eg, &gt;1 month) symptoms or in patients with underlying heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Surks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Surks.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: Individualize initial dose based on clinical status and gland size; free T<sub>4</sub> levels may be used to guide initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Free T<sub>4</sub> levels 1 to 1.5 times ULN</i>: 5 to 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Free T<sub>4</sub> levels &gt;1.5 to 2 times ULN (or iodine-induced thyrotoxicosis)</i>: 10 to 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Free T<sub>4</sub> levels &gt;2 times ULN</i>: 20 to 40 mg/day. To achieve euthyroidism more quickly and reduce GI-related adverse effects, may give in 2 to 3 divided doses (especially with doses &gt;30 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-26670972','lexi-content-ref-Ross.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-26670972','lexi-content-ref-Ross.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dose adjustment: <b>Oral: </b>Usual maintenance dose: 5 to 10 mg once daily. Assess free T<sub>4</sub> and total T<sub>3</sub> at 4- to 6-week intervals; when normal, reduce dose by 30% to 50% and repeat thyroid function tests in 4 to 6 weeks; continue to adjust dose to achieve euthyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.2','lexi-content-ref-Ross.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.2','lexi-content-ref-Ross.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration of therapy: Depends on etiology and plans for definitive therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients undergoing definitive therapy</i>: Prior to definitive therapy, continue until euthyroid (typically 4 to 6 weeks); discontinue 2 to 3 days before radioactive iodine therapy or on the day of thyroidectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-16607544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-16607544'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients not undergoing definitive therapy: </i>For Graves disease, continue for 12 to 18 months, then assess for remission; for toxic multinodular goiter/toxic adenoma, continue indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Iodine-induced thyrotoxicosis</i>: Taper and discontinue therapy as iodine load is cleared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Surks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Surks.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm (alternative to propylthiouracil) (off-label use): Note:</b> Use in combination with other appropriate agents; if iodine is administered, delay iodine administration by ≥1 hour after methimazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 mg every 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.3','lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.3','lexi-content-ref-27521067'])">Ref</a></span>); once clinically stable, dose may be given less frequently (eg, 20 mg once or twice daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17127140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17127140'])">Ref</a></span>). In patients who cannot take methimazole by mouth, alternative administration routes (eg, nasogastric, rectal) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7054215','lexi-content-ref-Ross.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7054215','lexi-content-ref-Ross.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6885c9d-426a-42ba-9828-ce23c80618a9">Thyrotoxicosis, type I amiodarone-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxicosis, type I amiodarone-induced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 30 to 40 mg once daily; adjust dose to achieve euthyroidism (eg, free T<sub>4</sub>, total T<sub>3</sub>, TSH levels in the normal range); if high doses (eg, &gt;30 mg/day) are required after 3 to 6 months, it may be more effective to administer in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-26670972','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-26670972','lexi-content-ref-Ross.1'])">Ref</a></span>). <b>Note:</b> If etiology of amiodarone-induced thyrotoxicosis (eg, type I or type II) cannot be determined or if patient is clinically unstable, use in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Depends on whether amiodarone therapy will be continued:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuing amiodarone:</i> Continue methimazole indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Discontinuing amiodarone:</i> Taper methimazole slowly (eg, over months) to avoid recurrence of thyrotoxicosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990971"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32802086','lexi-content-ref-4042519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32802086','lexi-content-ref-4042519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~30% to 40%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24989959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24989959'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary; when scheduled dose falls on a hemodialysis day, administer after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24989959','lexi-content-ref-25089233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24989959','lexi-content-ref-25089233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Likely to be somewhat dialyzable: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary; when scheduled dose falls on a PIRRT day, administer after PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988340"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F194319"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F194331"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12592" href="/d/html/12592.html" rel="external">see "Methimazole: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a41aff3c-8618-4d56-b4f4-9502cf751d29">Hyperthyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism</b>: Infants, Children, and Adolescents: Oral: Initial: 0.4 mg/kg/<b>day</b> in 3 divided doses (approximately every 8 hours); maintenance 0.2 mg/kg/<b>day</b> in 3 divided doses (50% of initial)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdd2b5b5-47a6-4261-ae3c-50a8b4e96990">Graves disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graves disease</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>): <b>Note</b>: In severe cases, higher doses may be required (50% to 100% higher); once patient euthyroid, reduce dose by ≥50% to maintain euthyroid; duration of therapy usually 1 to 2 years</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing: Infants, Children, and Adolescents: Oral: Initial: 0.2 to 0.5 mg/kg/dose once daily (range: 0.1 to 1 mg/kg/dose)</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing (using <sup>1</sup>/<sub>4</sub>, <sup>1</sup>/<sub>2</sub>, or whole tablets): Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 1.25 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to 5 years: 2.5 to 5 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to 10 years: 5 to 10 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: 10 to 20 mg/day</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129913"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51129914"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56337502"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Agranulocytosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methimazole may cause <b>agranulocytosis</b>, a rare but potentially life-threatening adverse reaction that is reversible upon discontinuation. Patients should report immediately any sign/symptoms of infection (eg, fever, flu-like symptoms, pharyngitis) so a WBC can be assessed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8862963','lexi-content-ref-6687345','lexi-content-ref-15745981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8862963','lexi-content-ref-6687345','lexi-content-ref-15745981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: May be through direct toxicity, but more recent evidence supports an immune-mediated mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8862963','lexi-content-ref-15745981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8862963','lexi-content-ref-15745981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most cases occur within the first 3 months of treatment (mean 42 days) but can occur later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470834','lexi-content-ref-8862963','lexi-content-ref-15745981','lexi-content-ref-28105610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470834','lexi-content-ref-8862963','lexi-content-ref-15745981','lexi-content-ref-28105610'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Doses &gt;30 mg/day (possible risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6687345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6687345'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;40 years (possible risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6687345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6687345'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic variants: HLA-B*27:05 (Europeans) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31108563','lexi-content-ref-27157822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31108563','lexi-content-ref-27157822'])">Ref</a></span>); HLA‐B*38:02 (Han Chinese) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31108563','lexi-content-ref-26599303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31108563','lexi-content-ref-26599303'])">Ref</a></span>); HLA‐DRB1*08:03 (Han Chinese) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31108563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31108563'])">Ref</a></span>); Nox3 variants (encodes NADPH oxidase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28486791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28486791'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methimazole may rarely cause life-threatening <b>hepatotoxicity</b>, including <b>acute hepatic failure </b>and <b>hepatitis </b>(usually cholestatic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25279406','lexi-content-ref-12467281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25279406','lexi-content-ref-12467281'])">Ref</a></span>). Hepatotoxicity is reversible with discontinuation. Patients with hepatotoxicity due to methimazole may be at increased risk for hepatotoxicity with propylthiouracil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22332800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22332800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; not clearly established. Possible mechanisms include reactive metabolite formation and immune-mediated reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31240859','lexi-content-ref-31202168','lexi-content-ref-26498145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31240859','lexi-content-ref-31202168','lexi-content-ref-26498145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically within 2 days to 3 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31202168','lexi-content-ref-26498145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31202168','lexi-content-ref-26498145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17389704','lexi-content-ref-25279406','lexi-content-ref-12467281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17389704','lexi-content-ref-25279406','lexi-content-ref-12467281'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25279406','lexi-content-ref-12467281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25279406','lexi-content-ref-12467281'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Polymorphism in SLCO1B1*1a and SLCO1B1*1b (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31240859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31240859'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Carriers of the HLA-C*03:02 allele (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31202168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31202168'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lupus-like syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methimazole may cause a <b>lupus-like syndrome</b>, a rare but potentially life-threatening adverse reaction that is reversible with discontinuation and additional treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33349625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33349625'])">Ref</a></span>). Manifestations may range from cutaneous involvement to lupus <b>nephritis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8548997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8548997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; hypothesized to be an autoimmune response in genetically predisposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24557776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24557776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically manifesting weeks to months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33349625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33349625'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• IgA deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33349625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33349625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pancreatitis </b>is a rare, but potentially life-threatening adverse effect of methimazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32035032','lexi-content-ref-32813014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32035032','lexi-content-ref-32813014'])">Ref</a></span>). Pancreatitis is typically reversible upon discontinuation but has resulted in death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32895723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32895723'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related. While the exact mechanism is unknown, it follows a pattern of a hypersensitivity-type reaction with rechallenge reactions occurring at a shorter latency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32035032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32035032'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically occurs within the first 90 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32035032','lexi-content-ref-32380933','lexi-content-ref-32813014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32035032','lexi-content-ref-32380933','lexi-content-ref-32813014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813014'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vasculitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although this adverse reaction is more common with propylthiouracil, cases of <b>vasculitis</b> with methimazole have been discussed in the literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26414658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26414658'])">Ref</a></span>), most notably involving the kidneys, lungs, and skin. Many of these cases involve a positive antineutrophil cytoplasmic antibody (ANCA). ANCA-positive cases involve an inflammatory and necrotic process impacting small vessels. Pulmonary capillaritis and diffuse <b>pulmonary alveolar hemorrhage</b> has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29760925']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29760925'])">Ref</a></span>). This adverse reaction is potentially life-threatening without intervention but is reversible with discontinuation and supportive care. A review of ANCA-positive vasculitis cases possibly associated with methimazole reported a prevalence range of 0% to 16% with a median prevalence of 6% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26414658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26414658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; the median time to vasculitis presentation was 42 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26414658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26414658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29648530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29648530'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F194283"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, periarteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, skin pigmentation, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypothyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Enlargement of salivary glands, epigastric distress, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, drug fever, headache, paresthesia, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cerebral vasculitis (Tripodi 2008), hypersensitivity angiitis (Ribeiro 2013), vasculitis (Balavoine 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (Kubota 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Insulin autoimmune syndrome (Chen 2018, Gomez 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (Brix 2020), ageusia (Hallman 1953), gastrointestinal hemorrhage (Minkley 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Cooper 2005), aplastic anemia (Josol 2010), hypoprothrombinemia (Minkley 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Wang 2014), hepatitis (Wang 2014), hepatotoxicity (Wang 2014), jaundice (Wang 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuritis (Roldan 1972), neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (Beernaert 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Shell 2020), glomerulonephritis (Hori 1996), nephritis (Reynolds 1979)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary alveolar hemorrhage (Arai 2018)</p></div>
<div class="block coi drugH1Div" id="F194296"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to methimazole or any component of the formulation.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Breastfeeding, history of acute pancreatitis after administration of methimazole.</p></div>
<div class="block war drugH1Div" id="F194280"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects: Antithyroid agents have been associated with dermatologic reactions. Discontinue in the presence of a severe reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fever: Discontinue in the presence of unexplained fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: May cause hypothyroidism; routinely monitor TSH and free T<sub>4</sub> levels, adjust dose to maintain euthyroid state.</p></div>
<div class="block foc drugH1Div" id="F194291"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tapazole: 5 mg [DSC], 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F194276"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F194298"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (methIMAzole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.77</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867505"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tapazole: 5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tapazole: 10 mg, 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F5360379"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Rectal:</b> In thyroid storm, rectal administration has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7054215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7054215'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613280"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to food.</p></div>
<div class="block hazard drugH1Div" id="F49132856"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F194293"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hyperthyroidism:</b> Treatment of hyperthyroidism in patients with Graves disease or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not appropriate; amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy.</p></div>
<div class="block off-label drugH1Div" id="F25730657"><span class="drugH1">Use: Off-Label: Adult</span><p>Iodine-induced thyrotoxicosis; Thyroid storm; Thyrotoxicosis, type I amiodarone-induced</p></div>
<div class="block mst drugH1Div" id="F194356"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MethIMAzole may be confused with methazolAMIDE, metOLazone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F194344"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F194285"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antithyroid Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antithyroid agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): MethIMAzole may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid medications at least 3 days before sodium iodide I-131 administration, and avoid concurrent use.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52928959"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients taking methimazole should use effective contraception and postpone becoming pregnant until a stable euthyroid state is achieved. Patients taking methimazole should notify their health care provider immediately once pregnancy is suspected. The decision to continue antithyroid medications during pregnancy should be individualized (ATA [Alexander 2017]).</p></div>
<div class="block pri drugH1Div" id="F194299"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methimazole crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Congenital anomalies have been observed in neonates exposed in utero to methimazole in the first trimester and include anomalies of the upper GI tract (esophageal atresia with or without tracheoesophageal fistula), respiratory tract (choanal atresia), skin (aplasia cutis), and facial dysmorphism. Additional abdominal wall defects (umbilicocele), ventricular septal defects, and defects of the eye and urinary system have also been reported (ATA [Alexander 2017]). Hypothyroidism may occur in the newborn.</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled maternal hyperthyroidism may result in adverse neonatal and maternal outcomes. Adverse outcomes associated with poorly controlled thyrotoxicosis include pregnancy loss, pregnancy induced hypertension, maternal congestive heart failure, and thyroid storm, as well as prematurity, low birth weight, intrauterine growth restriction, and stillbirth (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">To avoid potential teratogenic effects, antithyroid drugs may be discontinued as soon as pregnancy is detected in select patients with well-controlled Graves disease at low risk for relapse; close monitoring of maternal and fetal thyroid function recommended (ATA [Alexander 2017]). When treatment is necessary, antithyroid drugs are the treatment of choice for the control of hyperthyroidism during pregnancy, although recommendations for specific agents vary by guideline. Methimazole is generally avoided during the first trimester but may be used later in pregnancy (ACOG 2020; ATA [Alexander 2017]). Dose requirements of methimazole may be decreased as pregnancy progresses. To prevent adverse pregnancy outcomes, the lowest effective dose should be used to keep the maternal TT4/FT4 at or just above the pregnancy specific upper limit of normal (ACOG 2020; ATA [Alexander 2017]).</p></div>
<div class="block brc drugH1Div" id="F194300"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Methimazole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Information related to the presence of methimazole in breast milk is available from 6 lactating women with Graves disease following a single dose of methimazole 15 mg. Peak methimazole concentrations were 0.32 ± 0.10 mcg/mL (breast milk) and 0.31 ± 0.09 mcg/mL (maternal plasma) 2 hours after administration. The half-life of methimazole was calculated to be 4.2 ± 0.8 hours in breast milk. Twelve hours after the dose, breast milk concentrations of methimazole had decreased to 0.03 ± 0.01 mcg/mL (Abe 1995).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Based on available data, thyroid function is normal in infants exposed to lower doses of methimazole via breast milk. In addition, IQ and physical development up to 74 months of age were not impaired in a long-term study of breastfed infants whose mothers were receiving treatment with methimazole. The treatment of hyperthyroidism in breastfeeding patients is the same as non-breastfeeding females. The lowest effective dose should be used; maternal doses of methimazole ≤20 mg/day are advised in breastfeeding patients. Infants exposed to antithyroid medications via breast milk should be monitored for adequate growth and development; routine tests of thyroid function are not recommended (ATA [Alexander 2017]). Taking the dose of methimazole after breastfeeding may help decrease potential infant exposure by providing a 3- to 4-hour interval before the next feed (Amino 2020).</p></div>
<div class="block mop drugH1Div" id="F194289"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Signs and symptoms of illness (ie, fever, sore throat, skin eruptions, general malaise).</p>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (baseline and if development of febrile illness or pharyngitis occurs); signs/symptoms of bone marrow suppression; prothrombin time (especially before surgical procedures); LFTs (bilirubin, alkaline phosphatase, ALT, AST) at baseline and if symptoms of liver injury occur (eg, anorexia, pruritus, right upper quadrant pain) (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid function tests:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum free T<sub>4</sub> and total T<sub>3</sub> at 4- to 6-week intervals during dose titration, then every 2 to 3 months once euthyroid levels are achieved (with long-term therapy [ie, &gt;18 months] may extend interval to every 4 to 6 months); in patients with Graves disease, if thyrotropin receptor antibodies (TRAbs) are negative, thyroid function tests should be monitored every 2 to 3 months for the first 6 months after discontinuing therapy, then at 4- to 6-month intervals for the next 6 months, then every 6 to 12 months thereafter (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Thyroid-stimulating hormone (TSH) periodically throughout treatment; TSH is not an adequate parameter to assess initial response as levels may remain suppressed for several months after starting therapy (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">TRAb in patients with Graves disease prior to stopping medication; elevation at the end of therapy decreases likelihood of remission (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnant patients: Free T4 and total T3 every 2 to 4 weeks until stabilized (ACOG 2020). Free T4, total T4, and TSH approximately every 4 weeks throughout pregnancy. TRAb once pregnancy is confirmed, at 18 to 22 weeks' gestation, and 30 to 34 weeks' gestation (ATA [Alexander 2017]).</p></div>
<div class="block pha drugH1Div" id="F194279"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits the synthesis of thyroid hormones by blocking the oxidation of iodine in the thyroid gland; blocks synthesis of thyroxine and triiodothyronine (T<sub>3</sub>); does not inactivate circulating T<sub>4</sub> and T<sub>3</sub></p></div>
<div class="block phk drugH1Div" id="F194295"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antithyroid: 12 to 18 hours (Clark 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 36 to 72 hours (Clark 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Almost complete (Clark 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Concentrated in thyroid gland, V<sub>d</sub>/F: 0.66 L/kg (Jansson 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: None (Cooper 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~93% (Clark 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 4 to 6 hours (Clark 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 2 hours (Clark 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;10% unchanged) (Jansson 1985).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038676"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Favistan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Danantizol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Favistan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Strumazol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Thyrozol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tapazol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tapazole</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Tirozol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Methimazole | Tapazole | Thyrozol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Metimazol | Metlina | Tapazol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Favistan | Thyrozol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Favistan | Thiamazol | Thiamazol "hennig" | Thiamazol Aristo | Thiamazol hexal | Thyrozol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Tiamazol 1A Farma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Tapazole | Tapel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Tapazol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mercazolyl | Thyrozol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tirodril</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Metimazol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Thyrozol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Unimazole</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Methimazole | Tapazole</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Athyrazol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Thyrozol | Velthrom</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mercaptizol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Methimercazole | Methimez</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mercazole</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Methimazole | Methimazole bukwang</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tapazol | Thyrozol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mercazolil | Metizol | Tapazole | Thiamazol | Thyrozol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Strumazol | Thyrozol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mercazolil | Thyrozol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Thyrozol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ganglioside | Tapazol | Tiahexal | Tiamazol | Tiamazol Armstrong | Tiarotec | Tizorol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Methimazole</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Strumazol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Tapazol | Thyrozol | Tiamazol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Methimazole | Strumazol | Tapazole | Tapdin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Favistan | Metizol | Thiamazole Merck | Thyrozol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Methimazole | Northyx | Tapazole</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Metibasol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Danantizol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mercazolil | Metizol | Thiamazole philopharm | Thyrozol | Tyrozol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Favistan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Thacapzol | Thiamazole uni pharma | Tiamazol 2care4 | Tiamazol abacus medicine | Tiamazol ebb | Tiamazol paranova</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Thyrozol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Athyrazol | Favistan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Favistan | Thyrozol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Methimazole | Tapazole | Timazol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Thiamazole uni pharma | Thyrozol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Perizol | Thyromazol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Based | Hontan | Lica | Medazole | Mepazole | Mercazole | Methimazole | Tapazole | Thimazol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mercazolil | Methizol | Thyrozol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Metidazol | Metimazol | Mmi</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tapazol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Thysedow</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7580275">
<a name="7580275"></a>Abe Y, Sato H, Sakai H et al. Antithyroid treatment of maternal hyperthyroidism during lactation. 11th International Thyroid Congress. Toronto, Ontario, Canada, September 10-15, 1995. Abstracts. <i>Thyroid</i>. 1995;5(suppl 1):S1-S275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/7580275/pubmed" id="7580275" target="_blank">7580275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32802086">
<a name="32802086"></a>Abdi H, Amouzegar A, Azizi F. Antithyroid drugs. <i>Iran J Pharm Res</i>. 2019;18(suppl 1):1-12. doi:10.22037/ijpr.2020.112892.14005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32802086/pubmed" id="32802086" target="_blank">32802086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. <i>Thyroid</i>. 2017;27(3):315-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443080">
<a name="32443080"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 223: Thyroid disease in pregnancy <i>Obstet Gynecol</i>. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32443080/pubmed" id="32443080" target="_blank">32443080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32651061">
<a name="32651061"></a>Amino N, Arata N. Thyroid dysfunction following pregnancy and implications for breastfeeding. <i>Best Pract Res Clin Endocrinol Metab</i>. 2020;34(4):101438. doi:10.1016/j.beem.2020.101438<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32651061/pubmed" id="32651061" target="_blank">32651061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470834">
<a name="17470834"></a>Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. <i>Ann Intern Med</i>. 2007;146(9):657-665. doi:10.7326/0003-4819-146-9-200705010-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/17470834/pubmed" id="17470834" target="_blank">17470834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29760925">
<a name="29760925"></a>Arai N, Nemoto K, Oh-Ishi S, Nonaka M, Hayashihara K, Saito T. Methimazole-induced ANCA-associated vasculitis with diffuse alveolar haemorrhage. <i>Respirol Case Rep</i>. 2018;6(5):e00315. doi:10.1002/rcr2.315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/29760925/pubmed" id="29760925" target="_blank">29760925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24557776">
<a name="24557776"></a>Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. <i>Lupus</i>. 2014;23(6):545-553. doi:10.1177/0961203314523871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/24557776/pubmed" id="24557776" target="_blank">24557776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26414658">
<a name="26414658"></a>Balavoine AS, Glinoer D, Dubucquoi S, Wémeau JL. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? <i>Thyroid</i>. 2015;25(12):1273-1281. doi:10.1089/thy.2014.0603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/26414658/pubmed" id="26414658" target="_blank">26414658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8862963">
<a name="8862963"></a>Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. <i>Drug Saf</i>. 1996;15(1):53-63. doi:10.2165/00002018-199615010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/8862963/pubmed" id="8862963" target="_blank">8862963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32895723">
<a name="32895723"></a>Bartalena L, Piantanida E, Tanda ML. Methimazole treatment and acute pancreatitis: both caution and reassurance are needed. <i>J Clin Endocrinol Metab</i>. 2020;105(12):dgaa636. doi:10.1210/clinem/dgaa636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32895723/pubmed" id="32895723" target="_blank">32895723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33349625">
<a name="33349625"></a>Beernaert L, Vanderhulst J. Antithyroid drug-induced lupus erythematosus and immunoglobulin A deficiency. <i>Am J Case Rep</i>. 2020;21:e927929. doi:10.12659/AJCR.927929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/33349625/pubmed" id="33349625" target="_blank">33349625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32035032">
<a name="32035032"></a>Brix TH, Lund LC, Henriksen DP, et al. Methimazole and risk of acute pancreatitis. <i>Lancet Diabetes Endocrinol</i>. 2020;8(3):187-189. doi:10.1016/S2213-8587(20)30025-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32035032/pubmed" id="32035032" target="_blank">32035032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26670972">
<a name="26670972"></a>Burch HB, Cooper DS. Management of Graves disease: a review [published correction appears in <i>JAMA</i>. 2016;315(6):614]. <i>JAMA</i>. 2015;314(23):2544-2554. doi:10.1001/jama.2015.16535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/26670972/pubmed" id="26670972" target="_blank">26670972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30572448">
<a name="30572448"></a>Chen F, Yang J, Liu Y, et al. Insulin autoimmune syndrome: three case reports. <i>Medicine (Baltimore)</i>. 2018;97(51):e13486. doi:10.1097/MD.0000000000013486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/30572448/pubmed" id="30572448" target="_blank">30572448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31108563">
<a name="31108563"></a>Chen WT, Chi CC. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: a systematic review and meta-analysis of pharmacogenomics studies. <i>Br J Clin Pharmacol</i>. 2019;85(9):1878-1887. doi:10.1111/bcp.13989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/31108563/pubmed" id="31108563" target="_blank">31108563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26599303">
<a name="26599303"></a>Cheung CL, Sing CW, Tang CS, et al. HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis. <i>Clin Pharmacol Ther</i>. 2016;99(5):555-561. doi:10.1002/cpt.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/26599303/pubmed" id="26599303" target="_blank">26599303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16885714">
<a name="16885714"></a>Clark SM, Saade GR, Snodgrass WR, et al. Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. <i>Ther Drug Monit.</i> 2006;28(4):477-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/16885714/pubmed" id="16885714" target="_blank">16885714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15745981">
<a name="15745981"></a>Cooper DS. Antithyroid drugs. <i>N Engl J Med.</i> 2005;352(9):905-917.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/15745981/pubmed" id="15745981" target="_blank">15745981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6687345">
<a name="6687345"></a>Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. <i>Ann Intern Med</i>. 1983;98(1):26-29. doi:10.7326/0003-4819-98-1-26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/6687345/pubmed" id="6687345" target="_blank">6687345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22759245">
<a name="22759245"></a>Gomez Cruz MJ, Jabbar M, Saini N, et al. Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. <i>Pediatr Diabetes</i>. 2012;13(8):652-655. doi:10.1111/j.1399-5448.2012.00884.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/22759245/pubmed" id="22759245" target="_blank">22759245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32380933">
<a name="32380933"></a>Guo JY, Chang CL, Chen CC. Association between thionamides and acute pancreatitis: a case-control study. <i>Thyroid</i>. 2020;30(11):1574-1578. doi:10.1089/thy.2019.0589<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32380933/pubmed" id="32380933" target="_blank">32380933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27157822">
<a name="27157822"></a>Hallberg P, Eriksson N, Ibañez L, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. <i>Lancet Diabetes Endocrinol</i>. 2016;4(6):507-516. doi:10.1016/S2213-8587(16)00113-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/27157822/pubmed" id="27157822" target="_blank">27157822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13044528">
<a name="13044528"></a>Hallman BL, Hurst JW. Loss of taste as toxic effect of methimazole (tapazole) therapy; report of three cases. <i>J Am Med Assoc</i>. 1953;152(4):322. doi:10.1001/jama.1953.63690040006007d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/13044528/pubmed" id="13044528" target="_blank">13044528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29648530">
<a name="29648530"></a>Hasegawa J, Hoshino J, Sekine A, et al. Clinical and histological features of antineutrophil cytoplasmic antibody-associated vasculitis related to antithyroid drugs . <i>Clin Nephrol</i>. 2018;89(6):438-444. doi:10.5414/CN109364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/29648530/pubmed" id="29648530" target="_blank">29648530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16889494">
<a name="16889494"></a>Hodak SP, Huang C, Clarke D, Burman KD, Jonklaas J, Janicic-Kharic N. Intravenous methimazole in the treatment of refractory hyperthyroidism. <i>Thyroid</i>. 2006;16(7):691-695. doi:10.1089/thy.2006.16.691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/16889494/pubmed" id="16889494" target="_blank">16889494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956314">
<a name="8956314"></a>Hori Y, Arizono K, Hara S, Kawai R, Hara M, Yamada A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. <i>Nephron</i>. 1996;74(4):734-735. doi:10.1159/000189486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/8956314/pubmed" id="8956314" target="_blank">8956314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jamp.1">
<a name="Jamp.1"></a>Jamp Methimazole (methimazole) [product monograph]. Boucherville, Quebec, Canada: Jamp Pharma Corporation; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4042519">
<a name="4042519"></a>Jansson R, Lindström B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. <i>Clin Pharmacokinet</i>. 1985;10(5):443-450. doi:10.2165/00003088-198510050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/4042519/pubmed" id="4042519" target="_blank">4042519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31240859">
<a name="31240859"></a>Jin S, Li X, Fan Y, et al. Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury. <i>Basic Clin Pharmacol Toxicol</i>. 2019;125(6):508-517. doi:10.1111/bcpt.13284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/31240859/pubmed" id="31240859" target="_blank">31240859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Johnson.1">
<a name="Johnson.1"></a>Johnson DG, Campbell S. Hormonal and metabolic agents. In: Bressler R, Katz MD, eds. <i>Geriatric Pharmacology.</i> McGraw-Hill; 1993:427-450.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22802368">
<a name="22802368"></a>Josol CV, Buenaluz-Sedurante M, Sandoval MA, Castillo G. Successful treatment of methimazole-induced severe aplastic anaemia in a diabetic patient with other co-morbidities. <i>BMJ Case Rep</i>. 2010;2010:bcr0520102993. doi:10.1136/bcr.05.2010.2993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/22802368/pubmed" id="22802368" target="_blank">22802368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8548997">
<a name="8548997"></a>Kawachi Y, Nukaga H, Hoshino M, Iwata M, Otsuka F. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. <i>Clin Exp Dermatol</i>. 1995;20(4):345-347. doi:10.1111/j.1365-2230.1995.tb01340.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/8548997/pubmed" id="8548997" target="_blank">8548997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24989959">
<a name="24989959"></a>Komine N, Kaizu K, Uriu K, Matsuoka-Ito A, Takeda Y, Nakamata T. Pharmacokinetics of the antithyroid drug thiamazole in a chronic hemodialysis patient with hyperthyroidism. <i>Clin Exp Nephrol</i>. 2002;6(3):170-174. doi:10.1007/s101570200030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/24989959/pubmed" id="24989959" target="_blank">24989959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27853063">
<a name="27853063"></a>Kubota S. Successful re-administration of low-dose of methimazole (MMI) in Graves' disease patients who experienced allergic cutaneous reactions to MMI at initial treatment and had received long-term propylthiouracil (PTU). <i>Intern Med</i>. 2016;55(22):3235-3237. doi:10.2169/internalmedicine.55.7281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/27853063/pubmed" id="27853063" target="_blank">27853063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31202168">
<a name="31202168"></a>Li X, Jin S, Fan Y, et al. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. <i>Biomed Pharmacother</i>. 2019;117:109095. doi:10.1016/j.biopha.2019.109095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/31202168/pubmed" id="31202168" target="_blank">31202168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methimazole.1">
<a name="Methimazole.1"></a>Methimazole tablet [prescribing information]. Congers, NY: Chartwell Pharmaceuticals LLC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21114679">
<a name="21114679"></a>Minkley L, Göhring-Frischholz K, Mörike K, Lauer UM, Müssig K. Severe gastrointestinal haemorrhage after methimazole intake. <i>Clin Endocrinol (Oxf)</i>. 2011;74(5):657-658. doi:10.1111/j.1365-2265.2010.03945.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/21114679/pubmed" id="21114679" target="_blank">21114679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7054215">
<a name="7054215"></a>Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. <i>J Clin Endocrinol Metab.</i> 1982;54(1):180-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/7054215/pubmed" id="7054215" target="_blank">7054215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17389704">
<a name="17389704"></a>Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. <i>J Clin Endocrinol Metab</i>. 2007;92(6):2157-2162. doi:10.1210/jc.2006-2135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/17389704/pubmed" id="17389704" target="_blank">17389704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127140">
<a name="17127140"></a>Nayak B, Burman K. Thyrotoxicosis and thyroid storm. <i>Endocrinol Metab Clin North Am.</i> 2006;35(4):663-686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/17127140/pubmed" id="17127140" target="_blank">17127140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332800">
<a name="22332800"></a>Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. <i>Clin Endocrinol (Oxf)</i>. 2012;77(2):310-315. doi:10.1111/j.1365-2265.2012.04365.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/22332800/pubmed" id="22332800" target="_blank">22332800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813014">
<a name="32813014"></a>Pecere A, Caputo M, Sarro A, et al. Methimazole treatment and risk of acute pancreatitis: a population-based cohort study. <i>J Clin Endocrinol Metab</i>. 2020;105(12):dgaa544. doi:10.1210/clinem/dgaa544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/32813014/pubmed" id="32813014" target="_blank">32813014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28486791">
<a name="28486791"></a>Plantinga TS, Arts P, Knarren GH, et al. Rare NOX3 variants confer susceptibility to agranulocytosis during thyrostatic treatment of Graves' disease. <i>Clin Pharmacol Ther</i>. 2017;102(6):1017-1024. doi:10.1002/cpt.733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/28486791/pubmed" id="28486791" target="_blank">28486791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-434980">
<a name="434980"></a>Reynolds LR, Bhathena D. Nephrotic syndrome associated with methimazole therapy. <i>Arch Intern Med</i>. 1979;139(2):236-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/434980/pubmed" id="434980" target="_blank">434980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23739718">
<a name="23739718"></a>Ribeiro Cde O, Magrin PF, Vilar EA, Durães SM, Estrella RR. Cutaneous leukocytoclastic vasculitis in the presence of methimazole therapy. <i>An Bras Dermatol</i>. 2013;88(2):283-286. doi:10.1590/S0365-05962013000200021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/23739718/pubmed" id="23739718" target="_blank">23739718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4508415">
<a name="4508415"></a>Roldan EC, Nigrin G. Peripheral neuritis after methimazole therapy. <i>N Y State J Med</i>. 1972;72(23):2898-2900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/4508415/pubmed" id="4508415" target="_blank">4508415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Amiodarone and thyroid dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2020d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.2">
<a name="Ross.2"></a>Ross DS. Thionamides in the treatment of Graves' disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.3">
<a name="Ross.3"></a>Ross DS. Thyroid storm. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.4">
<a name="Ross.4"></a>Ross DS. Treatment of toxic adenoma and toxic multinodular goiter. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30111225">
<a name="30111225"></a>Shell A, Sullivan JW. Acute kidney injury following methimazole initiation: a case report. <i>J Pharm Pract</i>. 2020;33(1):99-101. doi:10.1177/0897190018789277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/30111225/pubmed" id="30111225" target="_blank">30111225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25089233">
<a name="25089233"></a>So E, Arakaki R. Toxic multinodular goiter in a patient with end-stage renal disease and hemodialysis. <i>Hawaii J Med Public Health</i>. 2014;73(7):217-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/25089233/pubmed" id="25089233" target="_blank">25089233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.1">
<a name="Sperling.1"></a>Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Elsevier; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Surks.1">
<a name="Surks.1"></a>Surks MI. Iodine-induced thyroid dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tapazole.1">
<a name="Tapazole.1"></a>Tapazole (methimazole) [prescribing information]. Wilmington, NC: Pfizer Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tapazole.2">
<a name="Tapazole.2"></a>Tapazole (methimazole) [product monograph]. Saint-Laurent, Quebec, Canada: Paladin Labs Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18788922">
<a name="18788922"></a>Tripodi PF, Ruggeri RM, Campennì A, et al. Central nervous system vasculitis after starting methimazole in a woman with Graves' disease. <i>Thyroid</i>. 2008;18(9):1011-1013. doi:10.1089/thy.2008.0121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/18788922/pubmed" id="18788922" target="_blank">18788922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28105610">
<a name="28105610"></a>Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid drug-induced agranulocytosis: state of the art on diagnosis and management. <i>Drugs R D</i>. 2017;17(1):91-96. doi:10.1007/s40268-017-0172-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/28105610/pubmed" id="28105610" target="_blank">28105610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16607544">
<a name="16607544"></a>Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. <i>Eur J Nucl Med Mol Imaging</i>. 2006;33(6):730-737. doi:10.1007/s00259-006-0092-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/16607544/pubmed" id="16607544" target="_blank">16607544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25279406">
<a name="25279406"></a>Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. <i>Br J Clin Pharmacol</i>. 2014;78(3):619-629. doi:10.1111/bcp.12336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/25279406/pubmed" id="25279406" target="_blank">25279406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12467281">
<a name="12467281"></a>Woeber KA. Methimazole-induced hepatotoxicity. <i>Endocr Pract</i>. 2002;8(3):222-224. doi:10.4158/EP.8.3.222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/12467281/pubmed" id="12467281" target="_blank">12467281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26498145">
<a name="26498145"></a>Zou H, Jin L, Wang LR, Braddock M, Cai WW, Zheng MH. Methimazole-induced cholestatic hepatitis: two cases report and literature review. <i>Oncotarget</i>. 2016;7(4):5088-5091. doi:10.18632/oncotarget.6144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/26498145/pubmed" id="26498145" target="_blank">26498145</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9627 Version 352.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
